HBOT Conversations:
Elena Schertz & Tom Fox (Part 4) – Cancer & Cerebral Palsy
Elena Schetz, NP is the nurse practitioner, and Tom Fox is the Safety Director at Extivita-RTP. Extivita-RTP offers a positive environment for healing, and they encourage anyone seeking a better quality of life to come visit them and experience for themselves the wonder of Hyperbaric Oxygen Therapy.
Watch the Podcast
In a Special 5-part series with Extivita’s Nurse Practitioner, Elena Schertz, and Safety Director, Tom Fox, we dive into the extraordinary powers of HBOT, and the healing they have witnessed for a variety of conditions. The following segments prelude this episode:
Part 1 – HBOT for PTSD (veteran focus)
Part 2 – Concussions & HBOT
Part 3 – Heart Disease & HBOT
In Part 4 of 5, we discuss two topics — cancer & cerebral palsy.
Let’s start with cancer. Elena Schertz says cancer patients have come through the doors at Extivita many times, looking for a “Hail Mary”. They’ve done the chemo and radiation and they are now at the end of their rope, and don’t know what else to do. Elena believes that when it comes to cancer you should throw everything at it, monotherapy is not the answer. In the end, does it really matter which therapy worked?! As long as it works!! She will often discuss diet changes and recommend IV therapies like high dose vitamin C, Pulse Electromagnetic Therapy (PEMF – BEMER) along with Hyperbaric Oxygen Therapy. Elena explains that she’s seen impressive results using pro-oxidative treatments to help the patient kill cancer.
“I’ve seen patients who have reported to me that they have had their the tumor size shrink during the course of maybe 20 sessions.”
Elena reminds viewers that radiation necrosis is one of the covered indications by the FDA, so treatment is typically reimbursed by insurance. Since radiation kills the bad cells, and the good, hyperbarics can help the patient recover from radiation therapy by restoring oxygen to the good cells that were damaged in radiation field. HBOT can also be used in conjunction with chemotherapy to ease chemotherapy side effects (especially brain fog).
Tom explains that he has seen patients gain improvement in their biomarkers for cancer as a direct effect of receiving HBOT. And he has seen patients come in with brain cancer and glioblastoma, that were given nine months or three months to live. One particular patient comes to mind who Tom treated with HBOT and is now living 2 years post diagnosis and was only given months to live; HBOT was one of many therapies the patient has been using. It’s important to understand that its the incorporation of Hyperbaric Oxygen Therapy that makes the tumor happy. Happy tumors are calm, while aggravated tumors grow. By giving the tumor oxygen under pressure, it interrupts the metabolism of the tumor. He further explains that typically the inside of a tumor is hypoxic (oxygen starved) so by adding oxygen to the tumor, it will counteract the growth of the tumor.
Tom explains that it’s important to understand the role of oxygen in healing, and he recommends the Flexner Report to those who want to know more on medical education and emphasizing the science.
Tom says he would tell doctors & healers, “Hey, listen, practice your art. Practice the art of healing. Use every tool available to you and you’ll see outcome, especially when you use and look at the role of oxygen in healing.”
In turn, host, Edward di Girolamo, pointed out that the Research Rundowns by HBOT News are great for better understanding the research behind HBOT in particular, because we try and point out if there’s a conflict of interest to the researchers and to the viewers/readers.
“There’s a lot of good science out there and it’s just being ignored or when it’s summarized by somebody that may be paid off because of a conflict of interest, they conclude something that’s completely inaccurate, and that’s what we try to point out in our Research Rundowns.”
This leads into a brief discussion on Cerebral Palsy and universal healthcare, as Tom highlights some research that falls right in line with what Edward mentioned. Tom tells his personal story about his two step-sons who were born with Cerebral Palsy and how Hyperbarics helped them tremendously in gaining a better quality of life.
The CP twins started receiving treatment at age 4. One never went back to a wheelchair after 24 HBOT treatments, while the other (who was more severely affected by CP) gained truck control and was now feeding himself. Today, at 27 years old, they have both had well over 1,500 HBOT treatments. One graduated from college and the other works in community awareness and teaches English as a second language.
Tom ponders whether cerebral palsy could be eliminated if a child is treated with HBOT extremely early in life, would it repair the oxygen deprived damage done to the brain at birth? He says there are many physicians who think it would, and would ease the impact of CP on medicine and society.
Guests

Elena Schertz, NP - Clinic Manager at Extivita RTP
Elena worked as a nurse in the pediatric oncology, cardiac, and surgical units at UNC hospitals for 15 years before deciding to work in integrative medicine. After years of working as a nurse, she decided to pursue her graduate degree, completing her masters with honors. She is board certified as a Family Nurse Practitioner (FNP) through the American Nurses Credentialing Center.
Elena’s passion for integrative medicine comes from her knowledge that the mind, body and psych/social/spiritual systems are not separate. The focus of Elena’s practice is to approach each of her patient’s healing process from the perspective of the whole, supported and grounded in safety and evidence-based medicine. She also maintains close consultative relationships with experts in the field to promote and enhance wellness for her patients. Elena joined the wonderful Extivita team in March 2019 and is thrilled to be a part of advancing health and wellness through hyperbaric medicine.

Thomas M. Fox, MAS,MS, CHT - Safety Director at Extivita RTP
Tom joined the Extivita team in 2022 as the Safety Director, helping Extivita to maintain a healthy and safe environment for exceptional patient care.
Extivita-RTP – Hyperbaric Oxygen Therapy Clinic
2012-D TW Alexander Drive
Durham, NC 27709
919-354-3775
919-354-3776
contact@extivita.org
https://www.extivita.org/
Subscribe Now, It’s Free!
Recent HBOT News
Healing under pressure: Inside a military hyperbaric chamber
At 16, she had a stroke. At 17, her town burned in the Camp Fire. Now, as her community rebuilds, she's healing thanks to hyperbaric therapy. SACRAMENTO, Calif — February 2, 2017, started off as an ordinary day for the Pipkin Family. Patrick and Stacey Pipkin just...
Clinical Trial – High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC),
which may evolve to acute chest syndrome (ACS), the most common cause of death among adult
patients with SCD. Currently, there is no safe and effective treatment to abort VOC or
prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including
hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a
very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among
factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one
of the most potent and readily alterable. Current guidelines recommend oxygen therapy in
patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal
oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients
at risk of secondary ACS because they may experience acute desaturation. In contrast, various
case series suggest a potential beneficial role of intensified oxygen therapy targeting
hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the
latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at
high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to
100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60
L/min (which generates positive airway pressure and dead space flushing, that may prevent
evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In
patients with acute respiratory failure, HFNO has been shown to improve patient's comfort,
oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of
VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage
(MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and
Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in
hospital wards.
Clinical Trial – Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot
Cancer Institute)will be enrolled in the study. Patients will receive Melphalan on day -2 and
HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is
documented, the patients will be seen in clinic at least weekly through day +100.

